Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis

A significant number of patients presenting with metastatic breast (MBC) will eventually develop central nervous system (CNS) metastasis as these patients have an estimated risk of CNS involvement as high as 14%[1]. Prior to improvements in targeted therapy and radiation therapy techniques, patients presenting with CNS metastasis had a median overall survival of less than 6 months[2,3]. Of note multiple intracerebral metastases at presentation limit surgical approaches and emphasizes the need for drug development[4].

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lAfIm2
via IFTTT